Abstract
The contemporary era is characterised by the development of knowledge economies in which scientific research and technical innovation are seen as the motor for growth and competitive advantage. Nowhere is this more apparent than in the biosciences, where the emerging bioeconomy is surrounded by high hopes, but remains an area with few working technologies entering routine use. These developments have focused scholarly attention on the performative role that sociotechnical expectations play in constituting new scientific and technological domains. However, relatively little is known about the role of expectations in the commercial development of new technologies, the commodification of knowledge and the creation of economic value. This article therefore seeks to address these questions by exploring the role of expectations in the creation of a new industrial sector based on the commercial development of neurotechnology in the United States. In particular, it will focus on the role of two types of ‘promissory organisation’ in the making of the neuroindustry, how different regimes of hope and promise have been constructed around distinct groups of companies, and the complex relationship between these regimes. In conclusion, some reflections will be made about the way in which high-technology industries, sociotechnical futures and new forms of promissory value are co-produced.
Similar content being viewed by others
References
Birch, K. and Tyfield, D. (2012) Theorizing the bioeconomy: Biovalue, biocapital, bioeconomics or … what? Science, Technology and Human Values 38 (3): 299–327.
Brown, N. (2003) Hope against hype – Accountability in biopasts, presents and futures. Science and Technology Studies 16 (2): 3–21.
Brown, N. (2005) Shifting tenses: Reconnecting regimes of hope and truth. Configurations 13 (3): 331–335.
Brown, N. and Kraft, A. (2006) Blood ties: Banking the stem cell promise. Technology Analysis and Strategic Management 18 (3–4): 313–327.
Brown, N., Kraft, A. and Martin, P. (2006) The promissory pasts of blood stem cells. BioSocieties 1 (3): 329–348.
Brown, N., Rappert, B. and Webster, A. (2000) Contested Futures: A Sociology of Prospective Techno-Science. Farnham, UK: Ashgate.
Callon, M. (1998) Introduction: The embeddedness of economic markets in economics. In: M. Callon (ed.) The Laws of the Markets. Oxford: Blackwell, pp. 1–57.
Callon, M. (1986) Some elements of a sociology of translation: Domestication of the scallops and the fishermen of St Brieuc Bay. In: J. Law (ed.) Power, Action and Belief: A New Sociology of Knowledge. London: Routledge and Kegan Paul, pp. 196–223.
Caulfield, T. and Condit, C. (2012) Science and the sources of hype. Public Health Genomics 15: 209–217.
Cooper, M. (2008) Life as Surplus. Seattle, WA: University of Washington Press.
Deeds, D.L. and Hill, C.W.L. (1996) Strategic alliances and the rate of new product development: An empirical study of entrepreneurial biotechnology firms. Journal of Business Venturing 11 (1): 41–55.
DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003) The price of innovation: New estimates of drug development costs. Journal of Health Economics 22 (2): 151–185.
Gompers, P. and Lerner, J. (1999) The Venture Capital Cycle. Cambridge, MA: MIT Press.
Hedgecoe, A. and Martin, P. (2003) The drugs don’t work: Expectations and the shaping of pharmacogenetics. Social Studies of Science 33 (3): 327–364.
Helmreich, S. (2008) Species of biocapital. Science as Culture 17 (4): 463–478.
Hilgartner, S. (2007) Making the bioeconomy measurable: Politics of an emerging anticipatory machinery. Biosocieties 2 (3): 382–386.
Horst, M. (2007) Public expectations of gene therapy: Scientific futures and their performative effects on scientific citizenship. Science, Technology and Human Values 32 (2): 150–171.
Kaplan, S. and Murray, F. (2010) Entrepreneurship and the construction of value in biotechnology. Research on the Sociology of Organizations 29: 107–147.
Kollmer, H. and Dowling, M. (2004) Licensing as a commercialisation strategy for new technology-based firms. Research Policy 33 (8): 1141–1151.
Lerner, J. (1994) Venture capitalists and the decision to go public. Journal of Financial Economics 35 (3): 293–316.
Lerner, J. (1995) Venture capital and the oversight of private firms. The Journal of Finance 50 (1): 301–318.
Leyshon, A. and Thrift, N. (2007) The capitalization of almost everything. Theory, Culture & Society 24 (7–8): 97–115.
Lynch, Z. (2003) A politician who gets it. Brain Waves Blog, http://brainwaves.corante.com/archives/2003/02/, accessed 5 April 2012.
Lynch, Z. (2006a) Neurotechnology industry organization introduced. Brain Waves Blog 24th August 2006, http://brainwaves.corante.com/archives/nio/, accessed 5 April 2012.
Lynch, Z. (2006b) Welcome to our emerging neurosociety. Neurosociety Blog, http://www.neurosociety.com/home.html, accessed 13 March 2012.
Lynch, Z. (2009) New neurotech legislative initiative in early development. Brain Waves Blog, http://brainwaves.corante.com/archives/2009/12/10/new_neurotech_legislative_initiative_in_early_development.php, accessed 20 April 2012.
Lynch, Z. (2012a) About Zack Lynch. The Emerging Neurosociety Blog, http://www.neurosociety.com/aboutzacklynch.html, accessed 5 April 2012.
Lynch, Z. (2012b) Neurosociety press. Neurosociety Blog, http://www.neurosociety.com/neurosocietypress.html, accessed 5 April 2012.
Lynch, Z. and Laursen, B. (2009) The Neuro Revolution: How Brain Science is Changing our World. New York: St Martin’s Press.
Martin, P. (1995) The American gene therapy industry and the social shaping of a new technology. Genetic Engineer and Biotechnologist 15 (2–3): 155–167.
Martin, P., Brown, N. and Kraft, A. (2008) From bedside to bench? Communities of promise, translational research and the making of blood stem cells. Science as Culture 17 (1): 29–41.
Martin, P., Brown, N. and Turner, A. (2008) Capitalizing hope: The commercial development of umbilical cord blood stem cell banking. New Genetics and Society 27 (2): 127–143.
Moreira, T. and Palladino, P. (2005) Between truth and hope: On Parkinson’s disease, neurotransplantation and the production of the ‘self’. History of the Human Sciences 18 (3): 55–82.
NI Research (2012a) Consultation services. Corporate web site, http://www.neuroinvestment.com/consultation.html, accessed 2 May 2012.
NI Research (2012b) Publications. Corporate web site, http://www.neuroinvestment.com/publications.html, accessed 2 May 2012.
NIO (2012a) About the neurotechnology industry association. Corporate web site, http://www.neurotechindustry.org/aboutnio.html, accessed 5 April 2012.
NIO (2012b) NIO members list. NIO website, http://www.neurotechindustry.org/memberlist.html, accessed 19 April 2012.
NIO (2012c) National neurotechnology initiative overview. NIO website, http://www.neurotechindustry.org/neurotechinitiativesum.html, accessed 5 April 2012.
NIO (2012d) Promoting the neurotechnology industry. NIO website, http://www.neurotechindustry.org/industrypromotion.html, accessed 5 April 2012.
NIO (2012e) Summary of the national neurotechnology initiative act. NIO website, http://www.neurotechindustry.org/neurotechinitiativeleg.html, accessed 4 April 2012.
NeuroInsights (2011) Neurotechnology industry report 2011: Table of contents. Neurotechnology Industry Report 2011, http://www.neuroinsights.com/tableofcontents.html, accessed 30 April 2012.
NeuroInsights (2012a) Index definition and rules. Corporate web site, http://www.neuroinsights.com/neurotechindex/indexmethodology.html, accessed 2 May 2012.
NeuroInsights (2012b) Marker reports. Corporate web site, http://www.neuroinsights.com/marketreports.html, accessed 2 May 2012.
NeuroInsights (2012c) Market reports. Corporate web site, http://www.neuroinsights.com/marketreports.html, accessed 30 April 2012.
NeuroInsights (2012d) NeuroInsights neurotech stock universe. Corporate web site, http://www.neuroinsights.com/neurotechindex/neurotechstocks.html, accessed 30 April 2012.
NeuroInsights (2012e) Strategic advisory services. Corporate web site, http://www.neuroinsights.com/services.html, accessed 2 May 2012.
Neurotech Reports (2012a) About Neurotech reports. Neurotech Reports website, http://www.neurotechreports.com/pages/about.html, accessed 20 April 2012.
Neurotech Reports (2012b) The neurotechnology market. Neurotech Reports website, http://www.neurotechreports.com/pages/marketdata.html, accessed 30 April 2012.
Pollock, T.G. and Gulati, R. (2007) Standing out from the crowd: The visibility-enhancing effects of IPO-related signals on alliance formation by entrepreneurial firms. Strategic Organization 5 (4): 339–372.
Pollock, N. and Williams, R. (2010) The business of expectations: How promissory organizations shape technology and innovation. Social Studies of Science 40 (4): 525–548.
Seppa, T.J. and Laamanen, T. (2001) Valuation of venture capital investments: Empirical evidence. R and D Management 31 (2): 215–230.
Shane, S. and Stuart, T. (2002) Organizational endowment and the performance of university start-ups. Management Science 48 (1): 154–170.
Simakova, E. (2011) Collaboration talk: The folk theories of nano research. Science as Culture 21 (2): 177–203.
Sunder-Rajan, K. (2006) Biocapital: The Constitution of Postgenomic Life ande. Durham, NC: Duke University Press.
Tan, P.M.-S. and Lim, C.Y. (2007) The value relevance of accounting variables and analysts’ forecasts: The case of biotechnology firms. Review of Accounting and Finance 6 (3): 233–253.
Thurs, D.P. (2007) No longer academic: Models of commercialization and the construction of a nanotech industry. Science as Culture 16 (2): 169–186.
Tutton, R. (2011) Promising pessimism: Reading the futures to be avoided in biotech. Social Studies of Science 41 (3): 411–429.
van Lente, H. (1993) Promising Technology: The Dynamics of Expectations in Technological Development. Enschede, the Netherlands: University of Twente.
van Lente, H. and Rip, A. (1998) The rise of membrane technology: From rhetorics to social reality. Social Studies of Science 28 (2): 221–254.
Waldby, C. (2002) Stem cells, tissue cultures and the production of biovalue. Health 6 (3): 305–323.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martin, P. Commercialising neurofutures: Promissory economies, value creation and the making of a new industry. BioSocieties 10, 422–443 (2015). https://doi.org/10.1057/biosoc.2014.40
Published:
Issue Date:
DOI: https://doi.org/10.1057/biosoc.2014.40